Skip to main content
European Commission logo print header

European stroke prevention in reversible ischaemia trial (ESPRIT)

Objectif

Patients who have had a transient is haemic attack or no disabling is haemic stroke of arterial origin have an annual risk of 7 to 12 % for subsequent nonfatal stroke, nonfatal myocardial infarction or death (from all vascular causes) without treatment. The standard treatment acetylsalicylic acid (ASA) prevents only 13% of these events; this is far from ideal. Data from secondary prevention trials in other cerebrovascular diseases suggest that oral anticoagulation (AC) or ASA combined with dipyridamole are more effective in the secondary prevention. Since cerebrovascular disease is one of the major European health problems, especially in the elderly, it is of utmost importance to look for more effective prevention than that by ASA. ESPRIT is a randomised, international, multicoated trial in which three treatments are compared:
a) ASA,
b) ASA combined with dipyridamole
c) AC (INR 2-3). A total of 4500 patients will be enrolled.

Appel à propositions

Data not available

Coordinateur

UNIVERSITY MEDICAL CENTRE UTRECHT
Contribution de l’UE
Aucune donnée
Adresse
Heidelberglaan 100
3584CX UTRECHT
Pays-Bas

Voir sur la carte

Coût total
Aucune donnée

Participants (14)